BACKGROUND: Studies from every continent have shown that only around 50% of the patients subjected to thyroid hormone replacement have TSH in the normal range. However, to date, there are no consistent data about Brazil. OBJECTIVES: To evaluate levothyroxine (LT4) replacement treatment in patients with primary hypothyroidism followed in referral centers in Brazil. METHODS: Patients with primary hypothyroidism followed in referral centers (University Hospitals from Universidade Federal do Rio de Janeiro - UFRJ, Unicamp, Universidade Federal do Paraná - UFPR and Universidade Federal do Ceará-UFC) answered a questionnaire that inquired about clinical and biochemical conditions, social- economic status, life quality and clinicians' orientations as well as their understanding about the information given. Serum TSH was checked close to the interview. RESULTS: 2292 consecutive patients met the inclusion criteria. Mean age 51.2 yr and TSH values between 0.4 and 4.0 mUI/l were considered to be within the reference range. Among all patients taking thyroid medication, 42.7% had an abnormal serum TSH (28.3% were undertreated and 14.4% were overtreated). Approximately all patients (99%) took LT4 in the morning but less than 30 min before breakfast (85.4%). Regarding the clinicians' orientations: 97.5% of the patients were instructed to take the medication daily, and 92.6% to take 30 min before breakfast (92.6%). However, only 52.1% were told not to take LT4 along with other medication. CONCLUSIONS: Our study found that a significant number of patients taking thyroid hormones were not in the therapeutic range. Clinicians should, therefore, consider monitoring patients on thyroid replacement more frequently and being more precise on giving recommendations about the correct use of LT4.
BACKGROUND: Studies from every continent have shown that only around 50% of the patients subjected to thyroid hormone replacement have TSH in the normal range. However, to date, there are no consistent data about Brazil. OBJECTIVES: To evaluate levothyroxine (LT4) replacement treatment in patients with primary hypothyroidism followed in referral centers in Brazil. METHODS:Patients with primary hypothyroidism followed in referral centers (University Hospitals from Universidade Federal do Rio de Janeiro - UFRJ, Unicamp, Universidade Federal do Paraná - UFPR and Universidade Federal do Ceará-UFC) answered a questionnaire that inquired about clinical and biochemical conditions, social- economic status, life quality and clinicians' orientations as well as their understanding about the information given. Serum TSH was checked close to the interview. RESULTS: 2292 consecutive patients met the inclusion criteria. Mean age 51.2 yr and TSH values between 0.4 and 4.0 mUI/l were considered to be within the reference range. Among all patients taking thyroid medication, 42.7% had an abnormal serum TSH (28.3% were undertreated and 14.4% were overtreated). Approximately all patients (99%) took LT4 in the morning but less than 30 min before breakfast (85.4%). Regarding the clinicians' orientations: 97.5% of the patients were instructed to take the medication daily, and 92.6% to take 30 min before breakfast (92.6%). However, only 52.1% were told not to take LT4 along with other medication. CONCLUSIONS: Our study found that a significant number of patients taking thyroid hormones were not in the therapeutic range. Clinicians should, therefore, consider monitoring patients on thyroid replacement more frequently and being more precise on giving recommendations about the correct use of LT4.
Authors: B Biondi; E A Palmieri; S Fazio; C Cosco; M Nocera; L Saccà; S Filetti; G Lombardi; F Perticone Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: J Parle; L Roberts; S Wilson; H Pattison; A Roalfe; M S Haque; C Heath; M Sheppard; J Franklyn; F D R Hobbs Journal: J Clin Endocrinol Metab Date: 2010-05-25 Impact factor: 5.958
Authors: Wing May Kong; Maleyca H Sheikh; Peter J Lumb; Rossitza P Naoumova; Danielle B Freedman; Martin Crook; Caroline J Doré; Nicholas Finer; P Naoumova Journal: Am J Med Date: 2002-04-01 Impact factor: 4.965
Authors: José A Sgarbi; Fábio G Villaça; Benito Garbeline; Heloísa E Villar; João H Romaldini Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: Martin I Surks; Eduardo Ortiz; Gilbert H Daniels; Clark T Sawin; Nananda F Col; Rhoda H Cobin; Jayne A Franklyn; Jerome M Hershman; Kenneth D Burman; Margo A Denke; Colum Gorman; Richard S Cooper; Neil J Weissman Journal: JAMA Date: 2004-01-14 Impact factor: 56.272
Authors: N Sforza; J Rosenfarb; R Rujelman; M Rosmarin; E Blanc; C Frigerio; P Fossati; D Caruso; C Faingold; T Meroño; G Brenta Journal: J Endocrinol Invest Date: 2017-05-22 Impact factor: 4.256
Authors: Renato Bandeira de Mello; Karina Giassi; Gabriela Stahl; Maria Luisa Machado Assis; Marina Siqueira Flores; Bruna Cambrussi de Lima; Vanessa Piccoli; Ticiana da Costa Rodrigues Journal: Front Med (Lausanne) Date: 2022-06-23
Authors: Marjorie McMillan; Keith S Rotenberg; Kevin Vora; Arnold B Sterman; Lionel Thevathasan; Michael F Ryan; Munish Mehra; Walter Sandulli Journal: Drugs R D Date: 2016-03
Authors: Frank R Ernst; Peri Barr; Riad Elmor; Walter Sandulli; Lionel Thevathasan; Arnold B Sterman; Jessica Goldenberg; Kevin Vora Journal: Clin Drug Investig Date: 2017-01 Impact factor: 2.859
Authors: Juan J Díez; Pedro Iglesias; Agustín García; Ángel Mataix; Francisco A Bernabéu-Andréu Journal: Eur Geriatr Med Date: 2021-08-04 Impact factor: 1.710
Authors: Thaer Idrees; Wesley H Prieto; Sabina Casula; Aswathy Ajith; Matthew Ettleson; Flavia A Andreotti Narchi; Pedro S T Russo; Fernando Fernandes; Julie Johnson; Anoop Mayampurath; Rui M B Maciel; Antonio C Bianco Journal: J Endocr Soc Date: 2021-03-06